Key Laboratory of Hepatosplenic Surgery, Department of Hepatic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Department of Pediatric Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Cancer Lett. 2014 May 28;347(1):79-87. doi: 10.1016/j.canlet.2014.01.028. Epub 2014 Jan 31.
The present study aimed to investigate the anti-cancer effects of hydroxytyrosol (HT) in human hepatocellular carcinoma (HCC) cells. Our results show that HT could inhibit proliferation, induce G2/M cell cycle arrest and apoptosis in human HCC cells. Mechanically, we found that HT could suppress the activation of AKT and nuclear factor-kappa B (NF-κB) pathways. HT also significantly inhibited the tumor growth, angiogenesis and the activation of AKT and NF-κB pathways in an orthotopic model of human HCC in vivo. These data suggest that HT may be a promising candidate agent for the treatment of HCC.
本研究旨在探讨羟基酪醇（HT）对人肝癌（HCC）细胞的抗癌作用。我们的结果表明，HT 能够抑制人 HCC 细胞的增殖，诱导 G2/M 细胞周期阻滞和细胞凋亡。机制上，我们发现 HT 可以抑制 AKT 和核因子-κB（NF-κB）通路的激活。HT 还显著抑制了体内 HCC 原位模型中肿瘤生长、血管生成以及 AKT 和 NF-κB 通路的激活。这些数据表明，HT 可能是治疗 HCC 的一种有前途的候选药物。
